Latest Twitter Threads by @OncBrothers on Thread Reader App

Dec 10 • 5 tweets • 4 min read

#SABCS25 Day 1 Highlights #CommunityOnc:

1. #ALTERNATE: Surgery after NeoAdj ET

2. Role of NeoAdj Carbo in TNBC

3. #RJBC1501: Role of Carbo in Adj TNBC

4. #CITRINE: Role of Carbo in Adj TNBC

@SABCSSanAntonio @AACR #bcsm #OncTwitter @OncoAlert

1/5

1. #ALTERNATE: PhIII, Surgery after NeoAdj ET (NET) in postmeno pts with Stg II/III HR+/HER2-:

- Surgery in 70% after NET(43.8% were considered ineligible initially)
- Surgeons were less likely to omit ALND for LN+ after NET
- Need more data before omitting surgery here

2/5

https://twitter.com/to_be_elizabeth/status/1998525132768264534

Dec 9 • 10 tweets • 7 min read

Highlights from #ASH25 #CommunityOnc:

#Lymphoma
1. #EPCOREFL1 FL
2. #CLL17 CLL
3. #BRUIN313/314 CLL
4. #S1826 HL

#Myeloma
5. #COBRA
6. #MajesTEC3
7. #AQUILA
8. #RedirecTT1

#Leukemia
9. #PARADIGM

@ASH_hematology #lymsm #mmsm #HemeTwitter 1/10

1. #EPCOREFL1: PhIII, Epcoritamab + R2 (now approved) vs. R2 in 2L R/R follicular lymphoma:

- ORR: 95% vs. 79%
- CR: 83% vs. 50%
- ⬆️PFS (HR: 0.21)
- OS trending towards Epcor (HR: 0.38)
- AEs: ⬆️ Infections (33% ≥ Gr3), CRS 35% (0 ≥ Gr3)

2/10

https://twitter.com/mskcancercenter/status/1997710495634301430

Jun 3 • 8 tweets • 9 min read

Day 4 #ASCO25 Highlights:

1. #DestinyBreast09: 1L TDXd Her2+ MBC

2. #SOFT/TEXT: Adj endo breast ca

3. #CM816: NeoAdj Nivo/chemo NSCLC

4. #NeoADAURA: NeoAdj Osi mEGFR NSCLC

5. #DeLLphi304: 2L Tarla SCLC

6. #IMForte: 1L maint Lurbi ES-SCLC

7. Timings for IO

@ASCO

1/8

1. #DestinyBreast09: Ph III, TDXd + P vs THP in 1L metastatic Her2+ breast cancer.

- mPFS 40.7 vs 26.9mos (HR: 0.56)
- 15.2% vs 8.5% CRs
- Serious TAES: 27 vs 25.1%. Any grade ILD 12.1% vs 1%. 2 Gr5 ILDs with TDXd.

2/8

https://twitter.com/ptarantinomd/status/1929519600942612950

Jun 1 • 6 tweets • 3 min read

Day 3 #ASCO25 highlights: 5 plenary studies

1. #ATOMIC: Adj Atezo in Stg III colon ca

2. #NIVOPOSTOP: Adj Nivo in high risk head & neck ca

3. #VERIFY: Rusfertide in PV

4. #SERENA6: Camizestrant in ESR1m breast Ca

5. #MATTERHORN: Peri/PostOP Durva in GEJ/Gastric

@ASCO
1/6

1. #ATOMIC: Ph III, adj mFOLFOX + Atezolizumab vs. mFOLFOX in Stg III dMMR colon ca.

2/6

https://twitter.com/asco/status/1929245219519606976

May 31 • 8 tweets • 9 min read

Day 2 #ASCO25 highlights:

1. #VERITAC2: Vepdegestrant HR+ mBC

2. #INAVO120 (update): Inavolisib HR+ mBC

3. #ASCENT04: Sacituzumab mTNBC

4. #CM577 (update): Adj Nivo GEJ/Gastric

5. #DESTINYGastric04: TDXd HER2+ GEJ/Gastric

6. #KN564 (update): Adj Pembro ccRCC

@ASCO

1/8

1. #VERITAC2: Ph III,Vepdegestrant (PROTAC ER degrader) vs Fulvestrant after CDK4/6i + AI:

- mPFS 5.0 vs 2.1 mos in ESR1m (HR=0.57)
- No PFS benefit in all pts
- OS is immature
- Well-tolerated, low discontinuation
- New class of drug for ESR1m disease

2/8

https://twitter.com/erikahamilton9/status/1928792311279845813

May 30 • 7 tweets • 7 min read

Day 1 #ASCO25 highlights:

1. Review on recent approvals

2. #BREAKWATER (update): BRAF+ mCRC

3. #CM8HW (update): MSI-H mCRC

4. #DYNAMIC: ctDNA in colon ca

5. #CAIRO6: periOP Rx in peritoneal mets

#OncTwitter @ASCO

1/6

1. Recent @FDAOncology approvals:

- Tarlatamab: extensive stage small cell lung cancer

- Epcoritamab for R/R follicular lymphoma

- Dato-DXd: HR+ metastatic breast cancer

- Vorasidenib Gr2 Astrocytoma/Oligodendroglioma IDH1/2 +

2/6

Apr 30 • 5 tweets • 5 min read

#AACR25 highlights #CommunityOnc:

1. #KN689: PeriOP/PostOP Pembro in H&N

2. NeoAdj Dostarlimab in dMMR solid tumors

3. #BeamionLung1: Zongertinib in HER2 NSCLC

4. **Bonus from #AUA25 #SunRISE1 in NMIBC

#OncTwitter #MedTwitter @OncoAlert

1/5

1. #KN689: Ph 3, PeriOP/PostOP Pembro + SoC after surgery, LA(Stg III-IVA) HNSCC by @DrUppaluri

- ⬆️ EFS in all 51.8mos vs 30.4mos (⬆️ EFS in CPS≥10, HR 0.66)
- OS 🚫 statistically significant
- Comparison slide by @SuyogCancer
- Are you going to change your practice?

2/5

https://twitter.com/anavmanana/status/1916564233539735699

Mar 29 • 8 tweets • 8 min read

#ELCC25 highlights #CommunityOnc:

1. #KN799: ChemoIO + XRT StgIII

2. #LAURA Update: Osi StgIII

3 #MARIPOSA Update: Ami/Laz 1L mEGFR

4. #COCOON: AE mgmt for Ami

5. #SAVANNAH: 2L mEGFR->MET+

6. #MK3475AD77: SQ Pembro

7. #KRYSTAL7: 1L KRASG12C

#OncTwitter #lcsm @myESMO
1/8

1. #KN799: Ph 2, concurrent chemo-XRT + Pembro in Stg III unresectable NSCLC. #PACIFIC is the current SoC here.

- At 48mos, OS: 40.2% in cohort A (Sqm/Non-Sqm) & 46.3% in cohort B (non-sqm)
- ORR 71.4% in cohort A and 75.5% in Cohort B
- Gr 3-5 AEs 73% in cohort A

2/8

https://twitter.com/cancertheradvsr/status/1905630373721055495

Feb 16 • 7 tweets • 8 min read

#GU25 highlights #CommunityOnc:

1. Radical ✂️ vs. XRT high risk PCa

2. #TALAPRO2: PARPi in M1 CRPC

3. #EnzaP: ARPi + LuPSMA in M1 CRPC

4. #NIAGARA update: Resectable MIBC

5. #EV302 update: Metastatic #BladderCancer

6. #CM9ER update: 1L mRCC

#OncTwitter #gism @ASCO

1/7

1. In high-risk PCa: Radical prostatectomy vs RT w/ ADT (+/- chemo):

- Inverse probability of treatment weighting for distant mets ⬇️ in XRT 16% vs 23% w/ ✂️

- ⬆️ risk of death in XRT arm w/ no distant mets

- Multi modality remains the safer option!

2/7

https://twitter.com/drchoueiri/status/1890075387897782310

Jan 25 • 8 tweets • 8 min read

#GI25 highlights #CommunityOnc:

1. #SCIENCE: Adv Eso SCC

2. #ESOPEC publication (Eso/GEJ/Ga)

3. Chemo in resectable Panc Ca

4. #StarterNET: GEP-NET

5. #CM8HW: dMMR/MSI-H mCRC

6. #BREAKWATER: BRAFV600E mCRC

7. ctDNA: #BESPOKE + SWOG80702

#OncTwitter #gism @ASCO

1/8

1. #SCIENCE: Ph 3, resectable locally advanced ESCC, neo adj Rx: ChemoXRT vs ChemoXRT + Sintilimab (anti-PD1) vs Chemo + Sintilimab

- Significant ⬆️ in pCR w/ ChemoXRT + Sint (60%) vs ChemoXRT (47%) vs Chemo + Sint (13%)

- Awaiting longer term data before this becomes SoC

2/8

https://twitter.com/krishanjethwa/status/1882457858119446636

Dec 12, 2024 • 6 tweets • 6 min read

#SABCS24 Day 3 Highlights #CommunityOnc:

1. #EUROPA: ET vs XRT HR+ ≥70 yrs @Icro_Meattini

2. #PATINA: CDK4/6i HR+ HER2+ @DFCI_BreastOnc new SoC

3. #COMET: DCIS

4. #SUPREMO: XRT post mastectomy

5. #INSEMA: ALNBx early disease

@SABCSSanAntonio @AACR @UTHealthSAMDA

1/6

1. #EUROPA: Ph III, ET vs XRT after
surgery in ≥70 yrs HR+ luminal A-like early breast cancer. Median F/U: 2yrs

- Treatment-related AEs ⬇️ w/ XRT (67% vs 85%)
- ET was associated with a greater reduction in HRQOL but we need longer data for disease control

2/6

https://twitter.com/jenniferplichta/status/1867227161268257234

Dec 11, 2024 • 4 tweets • 4 min read

#SABCS24 Day 2 Highlights #CommunityOnc:

1. #EMBER3: Oral SERD in HR+

2. #OlympiA: PARPi in gBRCA

3. #Surgery in gBRCA

#bcsm @SABCSSanAntonio #OncTwitter #MedTwitter @UTHealthSAMDA @AACR

1. #EMBER3: Ph III, #Imlunestrant +/-#Abemaciclib in HR+ advanced BC @jhaveri_komal 👏👏

- Imlunestrant alone for mESR1(mPFS: 5.5mos vs 3.8mos)
- Combo⬆️ mPFS w/all comers (9.4mos vs 5.5mos), regardless of CDK4/6 exposure
- If co-PIK3CA, Capi or this combo? @DrHBurstein
2/4

https://twitter.com/ptarantinomd/status/1866872546987217386

Dec 11, 2024 • 5 tweets • 5 min read

#SABCS24 Day 1 Highlights #CommunityOnc:

1. @FDAOncology Reviews recent approvals: #Ribociclib & #Inavolisib

2. #PADMA: HR+ ET + CDK4/6i vs Chemo 1L

3. #DB06: HR+ TDXd

4. #KN522: biomarker analysis

@SABCSSanAntonio @AACR #bcsm #OncTwitter

1/5

1. Recent @US_FDA approvals:

a). #NATALEE: Adj #Ribociclib in HR+ Stg IIA - III, 400mg 3wks on, 1wk off for 3yrs. 3yr iDFS 90.7% vs 87.6, 3.1% absolute iDFS

b). #INAVO120: Inavolisib + Fulvestrant + Palbo vs Palbo/Fulvestrant HR+ mBC. PFS 15.0 vs 7.3mos (HR 0.43)

2/5

Dec 10, 2024 • 10 tweets • 11 min read

#ASH24 Highlights #CommunityOnc:

#Lymphoma
1. #POLARIX DLBCL
2. #inMIND FL
3. #TRIANGLE & #EA4151 MCL
4. #ENRICH MCL

#Myeloma
5. #AQUILA
6. Quad MetaAnalysis 1L
7. IVIG w/ BispecificAbs
8. #CARTITUDE4

#ITP
9. #LUNA3

@ASH_hematology #lymsm #mmsm #HemeTwitter 1/10

1. #POLARIX: 5yr update Pola-RCHP SoC R-CHOP (polatuzumab was approved in April 2023):

- PFS: 65% vs 59% (HR: 0.77)
- NO OS difference
- ORR/CR better in ABC/non-GCB type in R/R settings.
- Are you going to use Pola in 1L? All comers? Non-GCB? Only in R/R?

2/10

https://twitter.com/eddie_cliff/status/1865816722701459468

Sep 10, 2024 • 7 tweets • 6 min read

#WCLC24 Highlights #CommunityOncology:

1. #HARMONi2 in mNSCLC

2. #CM77TvsCM816 resectable NSCLC

3. #TROPIONLung01 in 2L mNSCLC

4. #SKIPPirr: AEs for Amivantamab

5. #TNM staging: 9th Ed

6. Personal highlights

#lcsm #OncTwitter @IASLC

1/7

1. #HARMONi2: 1L #ivonescimab (PD1/VEGF bispecific) mNSCLC PDL1 ≥ 1% vs Pembro alone.

- mPFS of 11.14 vs 5.8 mos
- ⬆️ PFS for PDL1 ≥ 50% (HR: 0.46)
- ⬆️ PFS for PDL1 1-49% (HR: 0.54), but SoC is Pembro + Chemo (🚫 single agent Pembro)
- 🇨🇳 only study, will need 🌎 study

2/7

https://twitter.com/drriyazshah/status/1832807001229054376

Jan 21, 2023 • 6 tweets • 4 min read

Day 3 #GI23 Highlights #CommunityOncology

1. #MOUNTAINEER: Tucat+Trast approved CRC

2. #SUNLIGHT: TAS102+Bev confirmed late option CRC

3. #E2211: Cape+Tem in pNET manuscript

4. #ctDNA kinetics CRC

5. TNT state in RectalCA

@ASCO #OncEd #MedEd @OncoAlert #GISM #MedTwitter 1. #MOUNTAINEER: Tucatinib + Trastuzumab now @US_FDA approved for RAS WT, HER2+ve mCRC that has progressed on upfront chemo:

- ORR 38%
- mDOR 12.4mos
- Common AEs: diarrhea, fatigue, rash, and pyrexia.

https://x.com/pashtoonkasi/status/1616413330926886912

Aug 10, 2022 • 6 tweets • 9 min read

#WCLC22 Highlights #CommunityOncology perspective:

1. #YESS Study - @RachM_UoN

2. #IMPower010 Update

3. #CALGB140503 - Sublobar resection

4. #SHAWL Study - @NarjustFlorezMD @jillfeldman4

5. #NADIM2 Trial by @MARIANOPROVENCI

1/6

#LCSM #MedTwitter @OncoAlert #OncEd @IASLC 1. #YESS Study @RachM_UoN: Lung CA screening with smoking cessation intervention concurrently:

- Smoking cessation is one of the most effective way to reduce lung CA mortality
- 33% quit at 3 months
- Women more likely to benefit

2/6

Share this page!

Enter URL or ID to Unroll